Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial

Klingbiel, D; Saridaki, Z; Roth, Arnaud; Bosman, F T; Delorenzi, M; Tejpar, S

doi:10.1093/annonc/mdu499

Scientific article

English

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial

ContributorsKlingbiel, D; Saridaki, Z; Roth, Arnaud; Bosman, F T; Delorenzi, M; Tejpar, S

Published inAnnals of oncology, vol. 26, no. 1, p. 126-132

Publication date2015

Abstract

Although colon cancer (CC) with microsatellite instability (MSI) has a more favorable prognosis than microsatellite stable (MSS) CC, the impact varies according to clinicopathological parameters. We studied how MSI status affects prognosis in a trial-based cohort of stage II and III CC patients treated with 5-fluorouracil (5-FU)/leucovorin or FOLFIRI.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Groupe Roth Arnaud (oncologie) (285)

Citation (ISO format)

KLINGBIEL, D et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. In: Annals of oncology, 2015, vol. 26, n° 1, p. 126–132. doi: 10.1093/annonc/mdu499

Article (Published version)

Identifiers

PID : unige:48094
DOI : 10.1093/annonc/mdu499
PMID : 25361982

Journal ISSN0923-7534

549views

0downloads

Creation10/03/2015 16:02:00

First validation10/03/2015 16:02:00

Update time14/03/2023 23:00:53

Status update14/03/2023 23:00:53

Last indexation30/10/2024 23:28:44

Archive ouverte UNIGE

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial

Technical informations